RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)

23 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering

19 сен 2022 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

19 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

14 сен 2022 21:20:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

14 сен 2022 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

07 сен 2022 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

06 сен 2022 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Investor Conferences in September

01 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 авг 2022 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference

03 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update

02 авг 2022 06:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

28 июл 2022 07:00:02 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

22 июл 2022 07:39:33 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

20 июл 2022 07:00:02 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

20 июл 2022 07:00:01 Источник Nasdaq GlobeNewswire

NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

18 июл 2022 05:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

12 июл 2022 06:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 июл 2022 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency

22 июн 2022 07:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment

22 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire